Review: Antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo

September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p45
Academic Journal
The article focuses on a study, which cites that antiviral agents reduce risk of influenza in healthy adults. They also alleviate symptoms faster than placebo. The study also researched whether antiviral agents improve outcomes in affected persons. Randomization method and allocation concealment were included in the quality assessment of trials. It was found that influenza and influenza-like illness was reduced in prophylaxis trials, amantadine, but not rimantadine, more than placebo.


Related Articles

  • COMMENTARY: Review: Antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo. Langley, Joanne M. // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p45 

    The article presents comments on studies related to examining whether antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo. For prophylaxis of exposed vulnerable persons or treatment of those at high risk for complications, the most commonly...

  • Influenza, Influenza Vaccine, and Amantadine/Rimantadine. Zimmerman, Richard Kent; Ruben, Frederick L.; Ahwesh, Ellen R. // Journal of Family Practice;Aug1997, Vol. 45 Issue 2, p107 

    Influenza viruses are highly contagious viruses that are transmitted from person to person, usually by the airborne route. Persons in semi-closed or crowded environments, such as students and residents of nursing homes, are at high risk of exposure. The illness attack rate in children ranges...

  • Amantadine: Does It Have a Role in the Prevention and Treatment of Influenza?  // Clinical Pediatrics;Jun1980, Vol. 19 Issue 6, p416 

    The article presents information on the role of amantadine in the prevention and treatment of influenza. Amantadine hydrochloride is an antiviral compound that is currently approved in the United States for the prevention and symptomatic management of the respiratory tract illness caused by...

  • Zanamivir for influenza virus infections. Adelman, Alan // Journal of Family Practice;Jan1998, Vol. 46 Issue 1, p17 

    The article presents a study, which examined the safety and effectiveness of zanamivir for the treatment of influenza virus infections. Influenza virus is a common source of infection during the winter months that cause significant morbidity and mortality. Amantadine and rimantadine are...

  • Review: antiviral agents reduce the risk of influenza in healthy adults and alleviate symptoms faster than placebo. Jefferson, T.; Demicheli, V.; Rivetti, D. // Evidence Based Medicine;Oct2006, Vol. 11 Issue 5, p141 

    The article presents a study conducted in Great Britain which showed that amantadine and neuraminidase inhibitors are effective in reducing the risk of symptomatic influenza in healthy adults. Some of the factors considered in the study include the cases of symptomatic influenza, alleviation of...

  • Scientists Disagree to Disagree on Influenza A Channel Structure. Breindl, Anette // BioWorld Today;1/31/2008, Vol. 19 Issue 21, p1 

    The article reports on two research groups, which presented in the January 31, 2008 issue of "Nature," what each believes to be the binding mechanism of the anti-influenza drug amantadine to its target, the M2 channel. It was noted that the two groups agree on the basic structure of the channel,...

  • …And Closing Down The M2 Channel.  // BioWorld Today;10/25/2010, Vol. 21 Issue 206, Special section p1 

    The article reports on the separate studies conducted by scientists from the University of Iowa and from the Florida State University and Brigham Young University, on the influenza viruses M2 channel, which is essential for viral replication and the target of anti-influenza drugs amantadine and...

  • Expanded vaccination for bird flu worth the investment.  // PharmacoEconomics & Outcomes News;2/6/2010, Issue 596, p7 

    The article discusses the research "Effectiveness and Cost-effectiveness of Expanded Antiviral Prophylaxis Andadjuvanted Vaccination Strategies for An Influenza A (H5N1) Pandemic," by N. Khazeni, published in an issue of "Annals of Internal Medicine."

  • Double dose of oseltamivir had no advantage in severe influenza.  // Infectious Disease News;Jul2013, Vol. 26 Issue 7, p17 

    The article discusses a study by the South East Asia Infectious Disease Clinical Research Network published in a 2103 issue of the "British Medical Journal" which showed that a second dose of oseltavimir for five days does not have a clinical or virological effect on patients with severe influenza.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics